The BioMedWire Podcast

AUSTIN, Texas, September 30, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features the return of Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. To begin the interview, Durkacz discussed Quantum BioPharma’s lead drug candidate, Lucid-MS, and its differentiated approach to addressing multiple sclerosis. “Lucid-MS is a drug that’s going to Phase 2. For the first time, this is going to be tested on patients with multiple sclerosis,” Durkacz said. “With MS, people start to lose control of their bodies. The reason is almost like a light bulb that starts flickering. The reason it’s flickering is because it’s connected by a copper wire with a plastic coating… The connectors from our brains have a protective coating as well, and that is called myelin. Lucid-MS is targeting myelin, which is totally different than every single drug today in the market for MS.” Durkacz then explained why the upcoming Phase 2 trial represents an important milestone for the Lucid-MS development program. “This is going to be the first time that patients with MS actually get to try Lucid-MS,” he said. “Phase 1 is done on healthy people… Phase 2 now allows us to test it on patients with MS, and we are looking very specifically for one thing: Does it help give them control back of their bodies? Because there is no drug in the world today that does that.” Turning to unbuzzd™, Durkacz highlighted the product’s clinical results as well as Quantum BioPharma’s equity interest in the company behind it. “unbuzzd™ is a powder that you put into water that is clinically proven to help you sober up from alcohol faster,” Durkacz said. “We published a peer-reviewed journal on the study in March of 2026, so people can go and actually see, and every single person tested in the study saw an increase in their blood alcohol metabolism rate… unbuzzd™ is going through an IPO process as we speak. When they go public and have raised money, they intend to do a full marketing launch of the product. Quantum BioPharma owns approximately 20% of unbuzzd™. We also have a royalty stream at 7% up to $250 million.” Join IBN’s Carmel Fisher for a fresh conversation with Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma, as he provides an update on the company’s Lucid-MS Phase 2 program, the development and commercial opportunity surrounding unbuzzd™, and the key milestones investors can watch for moving forward. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com To view Durkacz’s previous appearance on The BioMedWire Podcast, visit https://ibn.fm/EBAAZ The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.Ai/Timeline About Quantum BioPharma Ltd.  Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. ("Unbuzzd") (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. For more information, visit the company’s website at www.QuantumBioPharma.com About IBN IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.IBN.Ai Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements. Corporate Communications IBN Austin, Texas IBN.Ai 512.354.7000 Office [email protected]

AUSTIN, Texas, September 30, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features the return of Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. To begin the interview, Durkacz discussed Quantum BioPharma’s lead drug candidate, Lucid-MS, and its differentiated approach to addressing multiple sclerosis. “Lucid-MS is a drug that’s going to Phase 2. For the first time, this is going to be tested on patients with multiple sclerosis,” Durkacz said. “With MS, people start to lose control of their bodies. The reason is almost like a light bulb that starts flickering. The reason it’s flickering is because it’s connected by a copper wire with a plastic coating… The connectors from our brains have a protective coating as well, and that is called myelin. Lucid-MS is targeting myelin, which is totally different than every single drug today in the market for MS.” Durkacz then explained why the upcoming Phase 2 trial represents an important milestone for the Lucid-MS development program. “This is going to be the first time that patients with MS actually get to try Lucid-MS,” he said. “Phase 1 is done on healthy people… Phase 2 now allows us to test it on patients with MS, and we are looking very specifically for one thing: Does it help give them control back of their bodies? Because there is no drug in the world today that does that.” Turning to unbuzzd™, Durkacz highlighted the product’s clinical results as well as Quantum BioPharma’s equity interest in the company behind it. “unbuzzd™ is a powder that you put into water that is clinically proven to help you sober up from alcohol faster,” Durkacz said. “We published a peer-reviewed journal on the study in March of 2026, so people can go and actually see, and every single person tested in the study saw an increase in their blood alcohol metabolism rate… unbuzzd™ is going through an IPO process as we speak. When they go public and have raised money, they intend to do a full marketing launch of the product. Quantum BioPharma owns approximately 20% of unbuzzd™. We also have a royalty stream at 7% up to $250 million.” Join IBN’s Carmel Fisher for a fresh conversation with Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma, as he provides an update on the company’s Lucid-MS Phase 2 program, the development and commercial opportunity surrounding unbuzzd™, and the key milestones investors can watch for moving forward. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com To view Durkacz’s previous appearance on The BioMedWire Podcast, visit https://ibn.fm/EBAAZ The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.Ai/Timeline About Quantum BioPharma Ltd.  Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. ("Unbuzzd") (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. For more information, visit the company’s website at www.QuantumBioPharma.com About IBN IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.IBN.Ai Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements. Corporate Communications IBN Austin, Texas IBN.Ai 512.354.7000 Office [email protected]

AUSTIN, Texas, September 18, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Ehud Geller, Executive Chairman and CEO of Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions. To begin the interview, Geller provided an overview of Regentis’ regenerative medicine platform and its lead product, GelrinC®, which is being developed to treat cartilage injuries in the knee. “Our company, Regentis, is focused on developing technologies for regeneration of tissue, hence the name,” Geller said. “In our particular case, we have a platform from which we can develop a variety of applications. Currently, our lead product is called GelrinC®. Gelrin is the platform and C stands for cartilage, and we are specifically focused on treating cartilage injuries to the knee. We are already approved for marketing in Europe, and we are in the midst of our clinical trial, the pivotal trial which will get us permission from the FDA to start marketing in the U.S.” Turning to the market opportunity, Geller discussed the prevalence of cartilage injuries among knee-related conditions and the size of the U.S. market Regentis is targeting. “We believe that there are two layers to that market. The very obvious one: a patient comes to the doctor suffering from pain in his knee, and he would probably have one of three potential pathologies,” Geller said. “The major one, covering more than 50% of the cases, is ours. The total U.S. market annually is 470,000 cases a year, and that is the size of the market currently untreated.” Looking at Regentis’ priorities for the remainder of 2026, Geller highlighted continued enrollment in the company’s U.S. pivotal study as well as efforts to advance commercialization in Europe. “We want to finish enrolling the balance of our patients for the U.S. pivotal study, which we’re now running,” Geller said. “We’re in the midst of that study, and our team is right now opening more sites for a clinical study in the U.S. to speed up the enrollment, which we hope to finish by approximately the end of the year. Another thing that we’re doing is working quite actively on commercialization. We have approval in Europe, so we are permitted already to market and sell in Europe. Following our IPO, we started activities toward that. We are in discussion with a number of distribution systems and/or strategic major orthopedic companies in Europe.” To close the interview, Dr. Geller said, “The message we bring to the market is one of a short, 10-minute procedure with two weeks of recovery, and I must say we've put in front of us durability as a slogan for the company. We need to treat patients in a way that will hold for a long time.” Join IBN’s Stuart Smith for a conversation with Dr. Ehud Geller, Executive Chairman and CEO of Regentis Biomaterials, as he further explores GelrinC®, the company’s U.S. pivotal study and European commercialization strategy, the market opportunity for cartilage repair, its broader regenerative medicine platform, intellectual property portfolio and key development and commercial milestones. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.Ai/Timeline About Regentis Biomaterials Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC®, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC® aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. For more information, visit the company’s website at www.Regentis.co.il About IBN IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.IBN.Ai Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements. This content was disseminated on behalf of (NYSE American: RGNT) as part of a paid marketing engagement with IBN.Ai RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN Corporate Communications IBN Austin, Texas IBN.Ai 512.354.7000 Office [email protected]

AUSTIN, Texas, September 18, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Ehud Geller, Executive Chairman and CEO of Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions. To begin the interview, Geller provided an overview of Regentis’ regenerative medicine platform and its lead product, GelrinC®, which is being developed to treat cartilage injuries in the knee. “Our company, Regentis, is focused on developing technologies for regeneration of tissue, hence the name,” Geller said. “In our particular case, we have a platform from which we can develop a variety of applications. Currently, our lead product is called GelrinC®. Gelrin is the platform and C stands for cartilage, and we are specifically focused on treating cartilage injuries to the knee. We are already approved for marketing in Europe, and we are in the midst of our clinical trial, the pivotal trial which will get us permission from the FDA to start marketing in the U.S.” Turning to the market opportunity, Geller discussed the prevalence of cartilage injuries among knee-related conditions and the size of the U.S. market Regentis is targeting. “We believe that there are two layers to that market. The very obvious one: a patient comes to the doctor suffering from pain in his knee, and he would probably have one of three potential pathologies,” Geller said. “The major one, covering more than 50% of the cases, is ours. The total U.S. market annually is 470,000 cases a year, and that is the size of the market currently untreated.” Looking at Regentis’ priorities for the remainder of 2026, Geller highlighted continued enrollment in the company’s U.S. pivotal study as well as efforts to advance commercialization in Europe. “We want to finish enrolling the balance of our patients for the U.S. pivotal study, which we’re now running,” Geller said. “We’re in the midst of that study, and our team is right now opening more sites for a clinical study in the U.S. to speed up the enrollment, which we hope to finish by approximately the end of the year. Another thing that we’re doing is working quite actively on commercialization. We have approval in Europe, so we are permitted already to market and sell in Europe. Following our IPO, we started activities toward that. We are in discussion with a number of distribution systems and/or strategic major orthopedic companies in Europe.” To close the interview, Dr. Geller said, “The message we bring to the market is one of a short, 10-minute procedure with two weeks of recovery, and I must say we've put in front of us durability as a slogan for the company. We need to treat patients in a way that will hold for a long time.” Join IBN’s Stuart Smith for a conversation with Dr. Ehud Geller, Executive Chairman and CEO of Regentis Biomaterials, as he further explores GelrinC®, the company’s U.S. pivotal study and European commercialization strategy, the market opportunity for cartilage repair, its broader regenerative medicine platform, intellectual property portfolio and key development and commercial milestones. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.Ai/Timeline About Regentis Biomaterials Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC®, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC® aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. For more information, visit the company’s website at www.Regentis.co.il About IBN IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.IBN.Ai Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements. This content was disseminated on behalf of (NYSE American: RGNT) as part of a paid marketing engagement with IBN.Ai RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN Corporate Communications IBN Austin, Texas IBN.Ai 512.354.7000 Office [email protected]

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. Quantum BioPharma Ltd. (NASDAQ: QNTM) (Profile) has received FDA clearance to begin a phase 2 trial of Lucid-MS, a patented, first-in-class drug candidate aimed not at calming the immune system but at protecting and potentially repairing the myelin sheath itself. The clearance sets the stage for what would be the first time in history that a drug candidate built on this specific mechanism is tested in people living with the MS disease, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts. This momentum places Quantum BioPharma solidly in a group of leading companies focused on the treatment of serious diseases and areas of significant unmet medical need across vaccines, ophthalmology and neurological disease, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN). Research indicates that MS affects an estimated one million people in the United States and approximately 2.9 million people worldwide. The FDA’s clearance of Quantum BioPharma’s Investigational New Drug (“IND”) application marks a genuinely rare moment in MS research. In addition to the upcoming phase 2 drug trial, Quantum BioPharma has spent more than a year building a parallel research partnership with scientists at Massachusetts General Hospital (“MGH”) and Harvard Medical School. Lucid-MS, also known by its research designation Lucid-21-302, is built around a different theory of how to target MS progression. Clinical milestones matter to patients, but they also move markets, and Quantum BioPharma has recently drawn fresh attention from Wall Street analysts. For further information about Quantum BioPharma Ltd., visit the Quantum BioPharma profile. https://ibn.fm/CzNQ5   To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com  

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. Quantum BioPharma Ltd. (NASDAQ: QNTM) (Profile) has received FDA clearance to begin a phase 2 trial of Lucid-MS, a patented, first-in-class drug candidate aimed not at calming the immune system but at protecting and potentially repairing the myelin sheath itself. The clearance sets the stage for what would be the first time in history that a drug candidate built on this specific mechanism is tested in people living with the MS disease, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts. This momentum places Quantum BioPharma solidly in a group of leading companies focused on the treatment of serious diseases and areas of significant unmet medical need across vaccines, ophthalmology and neurological disease, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN). Research indicates that MS affects an estimated one million people in the United States and approximately 2.9 million people worldwide. The FDA’s clearance of Quantum BioPharma’s Investigational New Drug (“IND”) application marks a genuinely rare moment in MS research. In addition to the upcoming phase 2 drug trial, Quantum BioPharma has spent more than a year building a parallel research partnership with scientists at Massachusetts General Hospital (“MGH”) and Harvard Medical School. Lucid-MS, also known by its research designation Lucid-21-302, is built around a different theory of how to target MS progression. Clinical milestones matter to patients, but they also move markets, and Quantum BioPharma has recently drawn fresh attention from Wall Street analysts. For further information about Quantum BioPharma Ltd., visit the Quantum BioPharma profile. https://ibn.fm/CzNQ5   To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com  

Disseminated on behalf of Onco-Innovations Ltd., may include paid advertisements. AUSTIN, Texas, September 10, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF), a clinical-stage oncology company focused on advancing a new class of DNA Damage Response therapies and developing artificial intelligence-driven precision oncology solutions. To begin the interview, Mohamed provided an overview of Onco-Innovations’ lead drug candidate, ONC010, and the company’s work targeting PNKP, a DNA repair enzyme that has not previously been targeted in a clinical-stage program. “Onco-Innovations is a Canadian preclinical-stage precision oncology company. It’s headquartered in Calgary, and we’re developing a first-in-class DNA Damage Response inhibitor against a novel target,” Mohamed said. “That’s a DNA repair enzyme called polynucleotide kinase phosphatase, or PNKP. As far as we’re aware, there is no clinical-stage PNKP program anywhere in the world, and we hold exclusive worldwide rights to the University of Alberta’s foundational PNKP inhibitor patents together with an exclusive sublicense to the nanoparticle delivery platform that accompanies it.”

Disseminated on behalf of Onco-Innovations Ltd., may include paid advertisements. AUSTIN, Texas, September 10, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF), a clinical-stage oncology company focused on advancing a new class of DNA Damage Response therapies and developing artificial intelligence-driven precision oncology solutions. To begin the interview, Mohamed provided an overview of Onco-Innovations’ lead drug candidate, ONC010, and the company’s work targeting PNKP, a DNA repair enzyme that has not previously been targeted in a clinical-stage program. “Onco-Innovations is a Canadian preclinical-stage precision oncology company. It’s headquartered in Calgary, and we’re developing a first-in-class DNA Damage Response inhibitor against a novel target,” Mohamed said. “That’s a DNA repair enzyme called polynucleotide kinase phosphatase, or PNKP. As far as we’re aware, there is no clinical-stage PNKP program anywhere in the world, and we hold exclusive worldwide rights to the University of Alberta’s foundational PNKP inhibitor patents together with an exclusive sublicense to the nanoparticle delivery platform that accompanies it.”

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (Profile) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly targeting the myelin sheath that MS destroys, and this new drug candidate is preparing to enter phase 2 clinical trials. Quantum BioPharma is one of several companies focused on the development and commercialization of therapies for neurological, autoimmune and immune-mediated diseases, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN). What makes MS particularly devastating is its progressive nature. Rather than targeting the immune system, Quantum BioPharma’s Lucid-MS targets the myelin sheath. The case for Lucid-MS is grounded in more than a decade of rigorous science. Quantum BioPharma’s path to phase 2 has been methodical and deliberate. To read the Full Publication, visit https://ibn.fm/wILk2 For further information about Quantum BioPharma Ltd., visit the Quantum BioPharma profile. To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com  

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (Profile) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly targeting the myelin sheath that MS destroys, and this new drug candidate is preparing to enter phase 2 clinical trials. Quantum BioPharma is one of several companies focused on the development and commercialization of therapies for neurological, autoimmune and immune-mediated diseases, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN). What makes MS particularly devastating is its progressive nature. Rather than targeting the immune system, Quantum BioPharma’s Lucid-MS targets the myelin sheath. The case for Lucid-MS is grounded in more than a decade of rigorous science. Quantum BioPharma’s path to phase 2 has been methodical and deliberate. To read the Full Publication, visit https://ibn.fm/wILk2 For further information about Quantum BioPharma Ltd., visit the Quantum BioPharma profile. To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com